Calidi Biotherapeutics (CLDI) Accounts Payables (2021 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Accounts Payables of $18000.0 for Q4 2025, up 800.0% year-over-year from $2000.0 in Q4 2024, and down 98.43% quarter-over-quarter from $1.1 million in Q3 2025.
Calidi Biotherapeutics (CLDI) Accounts Payables (2021 - 2026) Analysis & Trends
Calidi Biotherapeutics' Accounts Payables history runs 5 years deep, the most recent figure standing at $18000.0 for Q4 2025.
- In Q4 2025, Accounts Payables rose 800.0% year-over-year to $18000.0; the TTM figure through Dec 2025 stood at $18000.0 (up 800.0% YoY), while the FY2025 annual figure was $18000.0, up 800.0% from the prior year.
- Accounts Payables for Q4 2025 stood at $18000.0, down from $1.1 million in the prior quarter.
- The five-year high for Accounts Payables was $6.6 million in Q2 2024, with the low at $2000.0 in Q4 2024.
- The 5-year median for Accounts Payables is $142009.0 (2023), against an average of $1.5 million.
- Peak annual rise in Accounts Payables reached 4312.35% in 2024, while the deepest fall reached 99.97% in 2024.
- Calidi Biotherapeutics' Accounts Payables stood at $63839.0 in 2021, then soared by 3227.12% to $2.1 million in 2022, then soared by 187.19% to $6.1 million in 2023, then slumped by 99.97% to $2000.0 in 2024, then surged by 800.0% to $18000.0 in 2025.
- Business Quant data shows CLDI's Accounts Payables at $18000.0 in Q4 2025, $1.1 million in Q3 2025, and $1.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | 930,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 930,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Sep 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 7,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 6.60 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Dec 31, 2023 | 6.10 Mn |
| Sep 30, 2023 | 81,000.00 |
| Jun 30, 2023 | 487,324.00 |
| Mar 31, 2023 | 142,009.00 |
| Dec 31, 2022 | 2.12 Mn |
| Sep 30, 2022 | 103,082.00 |
| Jun 30, 2022 | 27,810.00 |
| Mar 31, 2022 | 41,518.00 |
| Dec 31, 2021 | 63,839.00 |